Johnson & Johnson Says Icotyde Shows 'Sustained' Psoriasis Clearance at Two Years

MT newswire2026/10/09 12:01

08:01 AM EDT, 10/09/2026 (MT Newswires) -- Johnson & Johnson (JNJ) reported Friday two-year phase 3 data showing "sustained" skin clearance with Icotyde in adults and adolescents with moderate-to-severe plaque psoriasis. At week 112, at least 72% of treated patients achieved 90% skin clearance, while at least 70% had clear or almost clear skin from week 64 through week 112, the company said. No new safety signals were identified through week 112, the company said.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

UK funds significantly reduced their holdings in SpaceX last week and had fully exited Tesla as of April.

格隆汇•2026/11/09 05:55

Swiss Franc weakens as Fed hawkish outlook lifts USD/CHF

FXStreet•2026/11/09 05:45

Sun Machinery CEO Park Kyung-hee Raises Stake to 8.40% From 8.31%

Bitget•2026/11/09 05:37

The central bank has increased its gold reserves for 24 consecutive months, with October’s increase hitting a record high for the period.

新浪财经•2026/11/09 05:37